Clinical pharmacology and therapeutic potential of monoclonal antibody treatment in rheumatoid arthritis

Drugs and Aging

Volumn 12, Issue 2, 1998, Pages 139-148

  Choy, Ernest H S ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AUTOANTIBODY; CD5 PLUS; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 6 ANTIBODY; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; OKT 4; PRILIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; ZOLIMOMAB ARITOX;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGENICITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; FATIGUE; FEVER; HEADACHE; HOT FLUSH; HUMAN; HYPOTENSION; INFECTION; INFLAMMATION; INTRAMUSCULAR DRUG ADMINISTRATION; KIDNEY DISEASE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; META ANALYSIS; MOUTH ULCER; MUSCLE WEAKNESS; MYOSITIS; NAUSEA; PATHOGENESIS; PRIORITY JOURNAL; RASH; REVIEW; RHEUMATOID ARTHRITIS; RIGOR; RISK; SUBCUTANEOUS DRUG ADMINISTRATION; URTICARIA; VOMITING;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CELL ADHESION MOLECULES; CLINICAL TRIALS; CYTOKINES; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; TREATMENT OUTCOME;

EID: 0031918616     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199812020-00006     Document Type: Review

References (51)

1. Köhler G, Milstein C. Continuous cultures of fused cells secret ing antibody of predefined specificity. Nature 1975; 256: 495-7
2. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994; 17: 992-9
3. Kavanaugh AF, Schulze-Koops H, Davis LS, et al. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule-1 monoclonal antibody. Arthritis Rheum 1997; 40: 849-53
4. Winter G, Milstein C. Man-made antibodies. Nature 1991; 349: 293-9
5. Marks C, Marks JD. Phage libraries - a new route to clinically useful antibodies. N Engl J Med 1996; 335: 730-3
6. Scott DL, Symmons DP, Coulton BL, et al. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987; 1: 1108-11
7. Pincus T, Marcum SB, Callahan LF. Long term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19: 1885-94
8. Isler P, Vey E, Zhang J, et al. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monicytic cells: a possible role of CD69. Eur Cytokine Netw 1993; 4: 15-23
9. Paulnock DM. Macrophage activation by T cells. Curr Opin Immunol 1992; 4: 344-9
10. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992; 4: 754-9
11. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992; 35: 729-35
12. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum 1990; 33: 768-73
13. Brennan FM, Maini RN, Feldmann M. TNF alpha - a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31: 293-8
14. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31
15. Chu CQ, Field M, Allard S, et al. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992; 31: 653-61
16. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10
17. Rankin EC, Choy EH, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334-42
18. Choy EHS, Kassimos D, Kingslev GH, et al. The effect of an engineered human anti-tumour necrosis factor alpha (TNFα) antibody (Ab) on interleukin-6 (IL-6) and bone markers in rheumatoid arthritis (RA) patients [abstract]. Arthritis Rheum 1995; 38 Suppl.: S185
19. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7
20. Rankin ECC, Choy EHS, Sopwith M, et al. Repeated doses of 10mg/kg of an engineered human anti-TNFα antibody. CDP571, in RA patients are safe and effective [abstract]. Arthritis Rheum 1995; 38 Suppl.: S185
21. Rankin ECC, Ravirajan CT, Ehrenstein MR, et al. Serological effects following treatment with an engineered human anti-TNFα antibody, CDP571 in patients with rheumatoid arthritis (RA) [abstract]. Br J Rheumatol 1995; 34 Suppl. 1: 101
22. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993; 20: 259-62
23. Pitzalis C, Kingsley G, Panayi G. Adhesion molecules in rheumatoid arthritis: role in the pathogenesis and prospects for therapy. Ann Rheum Dis 1994; 53: 287-8
24. Davis LS, Kavanaugh AF, Nichols LA, et al. Alteration in circulating T cell subsets as a result of treatment of rheumatoid arthritis patients with a monoclonal antibody to intercellular adhesion molecule-1 (ICAM-1) [abstract]. Arthritis Rheum 1992; 35: S43
25. Quagliata F, Schenkelaars EJ, Ferrone S. Immunotherapeutic approach to rheumatoid arthritis with anti-idiotypic antibodies to HLA-DR4. Isr J Med Sci 1993; 29: 154-9
26. Isaacs JD, Watts RA, Hazelman BL, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748-52
27. Olsen NJ, Brooks RH, Cush JJ, et al. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1102-8
28. Choy EHS, Chikanza IC, Kingsley GH, et al. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 1992; 36: 291-8
29. Moreland LW, Bucy RP, Tilden A, et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993; 36: 307-18
30. van der Lubbe PA, Dijkmans BA, Markusse HM, et al. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995; 38: 1097-106
31. Kirkham BW, Pitzalis C, Kingsley GH, et al. Monoclonal antibody treatment in rheumatoid arthritis: clinical and immunological effects of a CD7 monoclonal antibody. Br J Rheumatol 1991; 30: 459-63
32. Kirkham BW, Thien F, Pelton BK, et al. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992; 19: 1348-52
33. Lazarovits AI, White MJ, Karsh J. CD7 T cells in rheumatoid arthritis. Arthritis Rheum 1992; 35: 615-24
34. Strand V, Lipsky PE, Cannon GW, CD5 Plus Rheumatoid Arthritis Investigators Group, et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: results of two phase II studies. Arthritis Rheum 1993; 36: 620-30
35. Isaacs JD, Manna VK, Rapson N, et al. Campath-1H in rheumatoid arthritis - an intravenous dose-ranging study. Br J Rheumatol 1996; 35: 231-40
36. Ruderman EM, Weinblatt ME, Thurmond LM, et al. Synovial tissue response to treatment with Campath-1H. Arthritis Rheum 1995; 38: 254-8
37. Poynton CH, Mort D, Maughan TS. Adverse reactions to Campath-1H monoclonal antibody [letter]. Lancet 1993; 341: 1037
38. Matteson EL, Yocum DE, St Clair EW, et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum 1995; 38: 1187-93
39. Van den Broek MF, Van de Langerijt LG, Van Bruggen MC, et al. Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis. Eur J Immunol 1992; 22: 57-61
40. Horneff G, Burmester GR, Emmrich F, et al. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991; 34: 129-40
41. Reiter C, Kakavand B, Rieber EP, et al. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151: clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum 1991; 34: 525-36
42. Wendling D, Wijdenes J, Racadot E, et al. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J Rheumatol 1991; 18: 325-7
43. van der Lubbe PA, Reiter C, Breedveld FC, et al. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 1993; 36: 1375-9
44. Moreland LW, Pratt PW, Mayes MD, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995; 38: 1581-8
45. Choy EH, Pitzalis C, Cauli A, et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement, implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 1996; 39: 52-6
46. Herzog C, Walker C, Muller W, et al. Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells. J Autoimmunity 1989; 2: 627-42
47. Wendling D, Racadot E, Morel-Fourrier B, et al. Treatment of rheumatoid arthritis with anti-CD4 monoclonal antibody: open study of 25 patients with the B-F25 clone. Clin Rheumatol 1992; 11: 542-7
48. Epstein WV. Expectation bias in rheumatoid arthritis clinical trials: the anti-CD4 monoclonal antibody experience. Arthritis Rheum 1996; 39: 1773-80
49. Scoazec JY, Feldmann G. Both macrophages and endothelial cells of the human hepatic sinusoid express the CD4 molecule, a receptor for the human immunodeficiency virus. Hepatology 1990; 12: 505-10
50. Panayi GS, Choy EHS, Connolly DJA, et al. T cell hypothesis in rheumatoid arthritis (RA) tested by humanised non-depleting anti-CD4 monoclonal antibody (mAb) treatment: I. Suppression of disease activity and acute phase response [ahstract]. Arthritis Rheum 1996; 39 Suppl.: S244
51. Levy R, Weisman M, Wiesenhutter C, et al. Results of a placebo-controlled, multicenter trial using a primatized, non-depleting, anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39 Suppl.: S122